Is Eli Lilly Pulling Ahead in the Weight Loss Drug Battle?

Over the past few years, Eli Lilly (NYSE: LLY) has delivered strong returns, largely thanks to its clinical progress, particularly in one key area: weight management. The company's efforts in this niche are already paying rich dividends.However, the pharmaceutical leader isn't stopping yet. It already leads this area, and its recent developments suggest it could leave its competitors in the dust. Can any company catch up to Eli Lilly in the weight loss drug battle?It's worth noting that, although many companies are seeking to enter this market, only one poses a serious threat to Eli Lilly, and that's Novo Nordisk (NYSE: NVO). The Denmark-based pharmaceutical giant markets Wegovy, an anti-obesity medicine that generates billions in annual sales.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool